Quarterly report pursuant to Section 13 or 15(d)

Condensed Balance Sheets

 v2.3.0.11
Condensed Balance Sheets (USD $)
Jun. 30, 2011
Dec. 31, 2010
Assets:    
Cash and cash equivalents $ 16,127,716 $ 12,340,239
Marketable securities (note 4) 1,950,000 2,451,620
Research tax credit receivable 0 145,513
Prepaid expenses and other current assets (note 5) 486,098 706,649
Note receivable - current portion (note 6) 28,023 28,023
Total Current Assets 18,591,837 15,672,044
Restricted Cash Equivalents (note 18) 3,177,901 401,893
Note receivable (note 6) 4,671 18,682
Equipment, Net (note 7) 100,942 123,565
Total Assets 21,875,351 16,216,184
Liabilities:    
Accounts payable and accrued expenses (note 8) 3,891,616 1,820,900
Deferred Revenue (note 9) 862,500 900,000
Other Liabilities (note 10) 122,893 133,117
Warrant Liabilities (note 15) 5,519,955 2,966,710
Total Liabilities 10,396,964 5,820,727
Commitments and Contingencies (note 18)    
Stockholders' Equity (note 13):    
Preferred stock, par value $0.0001, 100,000,000 authorized shares, none issued and outstanding 0 0
Common stock, par value $0.0001, 500,000,000 authorized shares, 95,251,861 (2010 - 84,175,504) issued and 95,237,656 (2010 - 84,160,849) outstanding 9,525 8,418
Additional paid-in capital 67,501,948 56,157,452
Accumulated other comprehensive loss 0 (2,340)
Accumulated deficit during the development stage (56,004,676) (45,739,663)
Treasury stock, 14,205 shares, at cost (28,410) (28,410)
Total Stockholders' Equity 11,478,387 10,395,457
Total Liabilities and Stockholders' Equity $ 21,875,351 $ 16,216,184